GenPhar's ProVax and TheraVax technologies were developed from years of innovative research utilizing advanced molecular genetic techniques.
ProVax and TheraVax vaccines are safe, versatile, easy to produce, economical to manufacture and capable of inducing a full spectrum of protective immune responses.
ProVax and TheraVax vaccines are designed to protect against multiple virus subtypes in a single construct.
ProVax is GenPhar's vaccine technology for the prevention of disease caused by deadly viral pathogens. Using ProVax, GenPhar developed multivalent vaccines against Marburg, Ebola, a combination of Marburg/Ebola, and dengue viruses.
GenPhar's Ebola and Marburg vaccines achieved unprecedented results in U.S. Army challenge experiments by demonstrating 100% protective efficacy with no side effects or liver damage. Both vaccines are approaching human trials, and GenPhar's tetravalent dengue vaccine will follow in succession.
GenPhar has collaborative contracts with the U.S. Army, U.S. Navy and funding from NIH to continue its biodefense vaccine programs and provide vaccines to protect our troops and nation.
TheraVax is GenPhar's therapeutic vaccine technology. GenPhar uses TheraVax to develop vaccines for chronic viral diseases with heavy socio-economic impacts, like hepatitis B and hepatitis C. GenPhar's hepatitis B and hepatitis C vaccines halt the progression of the disease before it manifests into cirrhosis, cancer or other liver complications.
GenPhar's therapeutic HIV vaccine works to treat an HIV infection by stopping the disease's progression into AIDS. GenPhar's HIV vaccine produced results superior to competitors in tests conducted by the National Institute of Health (NIH).
A more detailed description of our vaccine candidates can be found here.